Inhibition of Dopamine-B-Hydroxylase in Manic Patients

A Clinical Trial With Fusaric Acid

Robert Sack, Frederick K. Goodwin

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Behavioral effects of fusaric acid, a specific inhibitor of dopaminebeta-hydroxylase (DBH), were evaluated under double-blind conditions in manic patients. Inhibition of DBH selectively decreases central norepinephrine (NE) without a decrease in dopamine and thus provides a test of the NE hypothesis of mania. Fusaric acid administration was associated with a significant decrease in cerebrospinal fluid 3-methoxy-4-hydroxy-phenylglycol (the major metabolite of NE) and an increase in homovanillic acid (the major metabolite of dopamine), changes consistent with central DBH inhibition. Behavioral effects of fusaric acid appeared to depend on the preexisting clinical state. Patients with more severe mania, including evidence of preexisting psychotic features, became consistently worse (more psychotic), while patients with mild hypomanic symptoms showed no change or slight improvement. Conventional antimanic therapies, initiated after the fusaric acid protocol, were associated with improvement in the expected time period in all patients.

Original languageEnglish (US)
Pages (from-to)649-654
Number of pages6
JournalArchives of General Psychiatry
Volume31
Issue number5
DOIs
StatePublished - 1974
Externally publishedYes

Fingerprint

Fusaric Acid
Mixed Function Oxygenases
Dopamine
Clinical Trials
Norepinephrine
Bipolar Disorder
Antimanic Agents
Homovanillic Acid
Cerebrospinal Fluid
Inhibition (Psychology)

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Psychiatry and Mental health

Cite this

Inhibition of Dopamine-B-Hydroxylase in Manic Patients : A Clinical Trial With Fusaric Acid. / Sack, Robert; Goodwin, Frederick K.

In: Archives of General Psychiatry, Vol. 31, No. 5, 1974, p. 649-654.

Research output: Contribution to journalArticle

Sack, Robert ; Goodwin, Frederick K. / Inhibition of Dopamine-B-Hydroxylase in Manic Patients : A Clinical Trial With Fusaric Acid. In: Archives of General Psychiatry. 1974 ; Vol. 31, No. 5. pp. 649-654.
@article{dabebd75e0764595ad3e65e72f2e407f,
title = "Inhibition of Dopamine-B-Hydroxylase in Manic Patients: A Clinical Trial With Fusaric Acid",
abstract = "Behavioral effects of fusaric acid, a specific inhibitor of dopaminebeta-hydroxylase (DBH), were evaluated under double-blind conditions in manic patients. Inhibition of DBH selectively decreases central norepinephrine (NE) without a decrease in dopamine and thus provides a test of the NE hypothesis of mania. Fusaric acid administration was associated with a significant decrease in cerebrospinal fluid 3-methoxy-4-hydroxy-phenylglycol (the major metabolite of NE) and an increase in homovanillic acid (the major metabolite of dopamine), changes consistent with central DBH inhibition. Behavioral effects of fusaric acid appeared to depend on the preexisting clinical state. Patients with more severe mania, including evidence of preexisting psychotic features, became consistently worse (more psychotic), while patients with mild hypomanic symptoms showed no change or slight improvement. Conventional antimanic therapies, initiated after the fusaric acid protocol, were associated with improvement in the expected time period in all patients.",
author = "Robert Sack and Goodwin, {Frederick K.}",
year = "1974",
doi = "10.1001/archpsyc.1974.01760170049008",
language = "English (US)",
volume = "31",
pages = "649--654",
journal = "JAMA Psychiatry",
issn = "2168-622X",
publisher = "American Medical Association",
number = "5",

}

TY - JOUR

T1 - Inhibition of Dopamine-B-Hydroxylase in Manic Patients

T2 - A Clinical Trial With Fusaric Acid

AU - Sack, Robert

AU - Goodwin, Frederick K.

PY - 1974

Y1 - 1974

N2 - Behavioral effects of fusaric acid, a specific inhibitor of dopaminebeta-hydroxylase (DBH), were evaluated under double-blind conditions in manic patients. Inhibition of DBH selectively decreases central norepinephrine (NE) without a decrease in dopamine and thus provides a test of the NE hypothesis of mania. Fusaric acid administration was associated with a significant decrease in cerebrospinal fluid 3-methoxy-4-hydroxy-phenylglycol (the major metabolite of NE) and an increase in homovanillic acid (the major metabolite of dopamine), changes consistent with central DBH inhibition. Behavioral effects of fusaric acid appeared to depend on the preexisting clinical state. Patients with more severe mania, including evidence of preexisting psychotic features, became consistently worse (more psychotic), while patients with mild hypomanic symptoms showed no change or slight improvement. Conventional antimanic therapies, initiated after the fusaric acid protocol, were associated with improvement in the expected time period in all patients.

AB - Behavioral effects of fusaric acid, a specific inhibitor of dopaminebeta-hydroxylase (DBH), were evaluated under double-blind conditions in manic patients. Inhibition of DBH selectively decreases central norepinephrine (NE) without a decrease in dopamine and thus provides a test of the NE hypothesis of mania. Fusaric acid administration was associated with a significant decrease in cerebrospinal fluid 3-methoxy-4-hydroxy-phenylglycol (the major metabolite of NE) and an increase in homovanillic acid (the major metabolite of dopamine), changes consistent with central DBH inhibition. Behavioral effects of fusaric acid appeared to depend on the preexisting clinical state. Patients with more severe mania, including evidence of preexisting psychotic features, became consistently worse (more psychotic), while patients with mild hypomanic symptoms showed no change or slight improvement. Conventional antimanic therapies, initiated after the fusaric acid protocol, were associated with improvement in the expected time period in all patients.

UR - http://www.scopus.com/inward/record.url?scp=0016174043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0016174043&partnerID=8YFLogxK

U2 - 10.1001/archpsyc.1974.01760170049008

DO - 10.1001/archpsyc.1974.01760170049008

M3 - Article

VL - 31

SP - 649

EP - 654

JO - JAMA Psychiatry

JF - JAMA Psychiatry

SN - 2168-622X

IS - 5

ER -